View More Recent Stories
-
Nuvalent (NUVL) Announces Public Offering of Common Stock
-
Nuvalent Inc (NUVL) Announces Publication in Cancer Discovery Detailing Design and Characterization of NVL-655
-
Baird Reiterates Outperform Rating on Nuvalent (NUVL)
-
Jefferies Reiterates Buy Rating on Nuvalent (NUVL)
-
Piper Sandler Reiterates Overweight Rating on Nuvalent (NUVL)
-
Nuvalent Inc (NUVL) Reports Latest Data on NVL-655
-
Barclays Reiterates Overweight Rating on Nuvalent (NUVL), PT $100
-
Piper Sandler Reiterates Overweight Rating on Nuvalent (NUVL)
-
Barclays Starts Nuvalent (NUVL) at Overweight
-
Nuvalent, Inc. (NUVL) Misses Q2 EPS by 12c
-
Nuvalent Inc (NUVL) Appoints Henry Pelish as Chief Scientific Officer
-
Nuvalent (NUVL) PT Raised to $115 at Stifel

